Interview with Kewal Handa, Managing Director, Pfizer Limited India
To start off, can you tell us how you have seen the pharmaceutical industry developing in India? Has the perception of India by big pharma changed over the years? First…
Address: First Floor, Su Motor Complex,, Veena Nagar, Mulund West, Mumbai-400 080,India
Tel: 022 30781000
Web: http://truecare.in/Truecare/
Abbott is a diverse global health care company with scientific expertise and products that address the varied healthcare needs of the people.
Abbott has been present in India for over 100 years now starting operations in 1910. The company’s pharmaceutical offerings expanded significantly over the years through organic growth and acquisitions. Currently Abbott is India’s largest pharmaceutical company in 2010 with the acquisition of Knoll, Solvay pharmaceuticals and Piramal Healthcare (domestic formulations division)
The product portfolio in India can be categorized into three broad categories – Pharmaceuticals, Nutrition and Medical devices.
Abbott serves the evolving healthcare needs of Indian consumers by introducing products backed by strong R&D. In addition our Established Pharmaceuticals Division (EPD) offers an expanding portfolio of branded generic drugs.
Our global citizenship priorities address the principal economic, social and environmental challenges necessary for a healthy society and a favorable business environment.
With over 13,000 people, India is Abbott’s largest employee base outside the United States. The company seeks to attract, retain and develop the best talent to ensure a healthy, safe, fulfilling work environment for all employees in India.
The product portfolio in India can be categorized into three broad categories – Pharmaceuticals, Nutrition and Medical devices.
Abbott serves the evolving healthcare needs of Indian consumers by introducing products backed by strong R&D. In addition our Established Pharmaceuticals Division (EPD) offers an expanding portfolio of branded generic drugs.
Our global citizenship priorities address the principal economic, social and environmental challenges necessary for a healthy society and a favorable business environment.
To start off, can you tell us how you have seen the pharmaceutical industry developing in India? Has the perception of India by big pharma changed over the years? First…
If we look back at the conditions under which you founded Biocon in 1978, we see a young woman with a seed capital of only Rs. 10,000 in a garage…
You have already publicly announced that, despite being late in India, Lonza has been increasingly looking into expanding in the Indian market. First of all, what do you think sparked…
Before moving into the company’s strategy, can you give our readers an idea of what role Boehringer Ingelheim India plays within the Group’s worldwide operations? Within the Boehringer Ingelheim Group,…
A catalyst of India’s shifting industry dynamics has been the sector’s M&A activity. We already saw majors such as Piramal going to Abbott and Ranbaxy to Daiichi-Sankyo… And while Andrew…
With the recent event “Vibrant Gujarat”, the state of Gujarat aimed to showcase the region’s opportunities and advanced infrastructure, hosting 1,400 delegates from 101 countries as well as several presentations…
You founded Calyx in 1979 with a three-person team. At the time, you were just 21 years old! What was the vision behind the creation of the company? Essentially, the…
You joined Wockhardt in 2000; you became a member of the board in 2006, and were appointed managing director in 2009. The Indian industry has undergone many changes in the…
Glenmark may be poised to release India’s first novel drug, from the in-licensed, anti-diarrheal molecule Crofelemer. Crofelemer has successfully complete Phase III trials, and you are readying to release it…
Since we last met in 2006, the Indian pharmaceutical industry has been doing very well indeed, as a very large number of drugs came off patent. This trend will continue…
Since we last met in 2006, the Indian pharmaceutical industry has been doing very well indeed, as a very large number of drugs came off patent. This trend will continue…
Our last report on India dates back to 2006, right after the Patent Law was passed. What developments have you seen happening in the industry since then? There has been…
See our Cookie Privacy Policy Here
